Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Cho, Yeoungjee ^a,b   Johnson, David W ^a,b   Vesey, David A ^a,b   Hawley, Carmel M ^a,b   Pascoe, Elaine M ^b   Clarke, Margaret ^c   Topley, Nicholas ^d  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Fresenius Medical Care   (Australia)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Biocompatible; Glucose degradation products; Interleukin 6; Peritoneal dialysis; Peritoneal solute transport rate; Peritonitis

Indexed keywords

GLUCOSE DEGRADATION PRODUCT; INTERLEUKIN 6;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIALYSATE; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONEAL SOLUTE TRANSPORT RATE; PERITONITIS; PH; RENAL SYSTEM PARAMETERS; SENSITIVITY ANALYSIS;

BIOLOGICAL MARKERS; DIALYSIS SOLUTIONS; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONITIS; REPRODUCIBILITY OF RESULTS; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84892403711     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-8     Document Type: Article

References (29)

1. Morphology of the peritoneum in CAPD. Dobbie JW, Blood Purif 1989 7 2-3 74 85 2663038 (Pubitemid 19115540)
2. Morphologic changes in the peritoneal membrane of patients with renal disease. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT, J Am Soc Nephrol 2002 13 2 470 479 11805177 (Pubitemid 34106290)
3. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Davies SJ, Phillips L, Russell GI, Nephrol Dial Transplant 1998 13 4 962 968 10.1093/ndt/13.4.962 9568858 (Pubitemid 28161772)
4. Higher membrane permeability predicts poorer patient survival. Fried L, Perit Dial Int 1997 17 4 387 389 9284467 (Pubitemid 27470215)
5. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. Rumpsfeld M, McDonald SP, Johnson DW, J Am Soc Nephrol 2006 17 1 271 278 16306167
6. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA, Immunity 2001 14 6 705 714 10.1016/S1074-7613(01) 00151-0 11420041 (Pubitemid 32592418)
7. Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Witowski J, Jorres A, Coles GA, Williams JD, Topley N, Kidney Int 1996 50 4 1212 1223 10.1038/ki.1996.430 8887280 (Pubitemid 26342812)
8. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Pecoits-Filho RCM, Stenvinkel P, LIndholm B, Heimburger O, Perit Dial Int 2006 26 53 63 16538876 (Pubitemid 44339662)
9. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Oh KH, Jung JY, Yoon MO, Song A, Lee H, Ro H, Hwang YH, Kim DK, Margetts P, Ahn C, Nephrol Dial Transplant 2010 25 5 1639 1646 10.1093/ndt/gfp670 20061317
10. Independent Effects of Systemic and Peritoneal Inflammation on Peritoneal Dialysis Survival. Lambie M, Chess J, Donovan KL, Kim YL, Do JY, Lee HB, Noh H, Williams PF, Williams AJ, Davison S, et al. J Am Soc Nephrol 2013 24 2071 2080 10.1681/ASN.2013030314 24009237
11. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T, Perit Dial Int 2012 32 2 159 167 10.3747/pdi.2010.00234 21804136
12. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS, Kidney Int 2004 66 3 1257 1265 10.1111/j.1523-1755.2004.00879.x 15327425 (Pubitemid 39121036)
13. Biocompatible peritoneal dialysis solution preserves residual renal function. Kim S, Oh KH, Oh J, Kim SJ, Chung W, Song YR, Na KY, Oh YK, Ahn C, Kim SG, et al. Am J Nephrol 2012 36 4 305 316 10.1159/000342523 23007025
14. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, Ahlmen J, Larsson R, Ingman B, Simonsen O, et al. Perit Dial Int 2009 29 6 647 655 19910566
15. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, Chan IH, Chan HW, Li CS, Wong SS, Ho YW, et al. Perit Dial Int 2012 32 3 280 291 10.3747/pdi.2010.00176 22045098
16. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Kim S, Oh J, Chung W, Ahn C, Kim SG, Oh KH, Nephrol Dial Transplant 2009 24 9 2899 2908 10.1093/ndt/gfp054 19258384
17. Effects of Biocompatible versus Standard Fluid on Peritoneal Dialysis Outcomes. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, et al. J Am Soc Nephrol 2012 23 6 1097 1107 10.1681/ASN.2011121201 22440906
18. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. Johnson DW, Clarke M, Wilson V, Woods F, Brown FG, BMC Nephrol 2010 11 25 10.1186/1471-2369-11-25 20843375
19. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, et al. Nephrol Dial Transplant 2012
20. The Effects of Biocompatible Compared with Standard Peritoneal Dialysis Solutions on Peritonitis Microbiology, Treatment, and Outcomes: the balANZ Trial. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, et al. Perit Dial Int 2012 32 5 497 506 10.3747/pdi.2012.00052 22991015
21. Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Rumpsfeld M, McDonald SP, Purdie DM, Collins J, Johnson DW, Am J Kidney Dis 2004 43 3 492 501 10.1053/j.ajkd.2003.11. 010 14981608 (Pubitemid 38298209)
22. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy. Davies SJ, Kidney Int Suppl 2006 103 76 83 17080116
23. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. Cho JH, Hur IK, Kim CD, Park SH, Ryu HM, Yook JM, Choi JY, Choi HJ, Park JW, Do JY, et al. Nephrol Dial Transplant 2010 25 6 1964 1973 10.1093/ndt/gfp767 20100731
24. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Cooker LA LP, Holmes CJ, Jones S, Topley N, on behalf of the Bicarbonate/Lactate study group, Perit Dial Int 2001 21 Supplement 3 102 S107 11887802
25. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Yung S, Chan TM, Mediators Inflamm 2012 2012 484167 22577250
26. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, Williams JD, Rose-John S, Jones SA, Topley N, J Clin Invest 2003 112 4 598 607 12925700 (Pubitemid 38056344)
27. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, Lameire NH, J Am Soc Nephrol 2003 14 5 1296 1306 10.1097/01.ASN.0000060681.91079.30 12707398 (Pubitemid 36514669)
28. Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes. Cho Y, Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville N, Bannister KM, Clayton PA, Johnson DW, Clin J Am Soc Nephrol 2013 8 9 1556 1563 10.2215/CJN.12361212 23949232
29. Geographic and educational factors and risk of the first peritonitis episode in Brazilian Peritoneal Dialysis study (BRAZPD) patients. Martin LC, Caramori JC, Fernandes N, Divino-Filho JC, Pecoits-Filho R, Barretti P, Brazilian Peritoneal Dialysis Multicenter Study BG, Clin J Am Soc Nephrol 2011 6 8 1944 1951 10.2215/CJN.11431210 21737854